<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884845</url>
  </required_header>
  <id_info>
    <org_study_id>PM2734-A-003-08</org_study_id>
    <nct_id>NCT00884845</nct_id>
  </id_info>
  <brief_title>Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors</brief_title>
  <official_title>Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaMar</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of
      PM02734 administered in combination with erlotinib to determine the safety and tolerability
      and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the
      combination of PM02734 and erlotinib, in patients with advanced malignant solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I multicenter, open-label, dose-escalating clinical and pharmacokinetic trial of
      PM02734 administered in combination with erlotinib to determine the safety and tolerability
      and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the
      combination of PM02734 and erlotinib, determine the preliminary pharmacokinetics (PK) of the
      combination, evaluate the preliminary PK/pharmacodynamic correlation, evaluate the
      preliminary antitumor activity, perform a preliminary pharmacogenomic (PGx) study to explore
      molecular predictors of response to ErbB receptor antagonists and PM02734 in patient with
      advanced malignant solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability and to identify the dose limiting toxicity (DLT) and the recommended dose (RD) of the combination of PM02734 and erlotinib</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine preliminary: pharmacokinetics (PK) , PK / pharmacodynamic correlation, antitumor activity, pharmacogenomic (PGx) study to explore molecular predictors of response.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Advanced Malignant Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of i.v. infusions of PM02734 (on Days 1, 8 and 15) every three weeks and a daily oral dose of erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PM02734 and erlotinib</intervention_name>
    <description>PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Brand name: TARCEVA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Voluntary written informed consent form.

          -  Histologically or cytologically confirmed advanced malignant solid tumors.

          -  Measurable or non-measurable disease following (RECIST)

          -  Age ≥ 18 years.

          -  Life expectancy ≥ 3 months.

          -  Performance status ECOG ≤ 2.

          -  Recovery from any drug-related adverse events (AEs) derived from previous treatments.

          -  Appropriate bone marrow, liver and renal function.

          -  Left ventricular ejection fraction (LVEF) within normal limits for the institution.

          -  Women of childbearing potential must have a negative serum pregnancy test before study
             entry. Both men and women must agree to use a medically acceptable method of
             contraception throughout the treatment period and for three months after
             discontinuation of treatment.

        Exclusion Criteria:

          -  Prior therapy with PM02734.

          -  Pregnant or lactating women.

          -  Less than four weeks from radiation therapy.

          -  Evidence of progressive central nervous system (CNS) metastases. or any symptomatic
             brain or leptomeningeal metastases.

          -  Other relevant diseases or adverse clinical conditions.

          -  Any other major illness that, in the Investigator's judgment.

          -  Limitation of the patient's ability to comply with the treatment or to follow-up at a
             participating protocol.

          -  Ingestion of potent cytochrome CYP3A4 inhibitors.

          -  Treatment with any investigational product in the 30-day period prior to the first
             infusion.

          -  Known hypersensitivity to any component of PM02734 or erlotinib.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Pérez-Soler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center (NY - USA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rafael Rosell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Germans Trias i Pujol (Badalona - Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauricio Cuello, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Universitario Dexeus (Barcelona - Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Intituto Universitario Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2009</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PM2734</keyword>
  <keyword>Tumors</keyword>
  <keyword>PharmaMar</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Tarceva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

